External Menu Top

Vorträge des IMI Online-Seminars vom 29.02.2008  

The Innovative Medicines Initiative (IMI): Overview (PDF, 885 KB)
Matthias Gottwald, Bayer Schering Pharma AG, Berlin

Einbindung der Bundesregierung in IMI (PDF, 334 KB)
Dr. Kirsten Steinhausen, BMBF

  
IMI Strategic Research Agenda
Recommendations on predicting safety and efficacy of new medicines as well as plans to bridge gaps in knowledge management and in education and training are presented in the IMI Strategic Research Agenda. The IMI Strategic Research Agenda is a living document and will be up-dated as necessitated by scientific advances.
more information		  

Draft Scientific Priorities 2008 (PDF, 359 KB)
The IMI Governing Board approved Draft Scientific Priorities (summary of the research priorities to be addressed) for the first IMI Call on its first meeting. The Draft Scientific Priorities have been sent to the IMI Member States Group for advice.

  

IMI Keys for Success - Industry Input (PDF, 183 KB)
The pharmaceutical industry represented by the EFPIA is convinced that the Innovative Medicines Initiative (IMI) will help create an environment, which will lead to additional private investment in pharmaceutical and biotechnology R&D across Europe.

  

IMI Intellectual Property Policy (PDF, 163 KB)
This IPR policy is a consensus document agreed upon after an intensive discussion process of more than one year. It will be the framework for the first calls and may be adapted mid term based on the experience from the first projects.

 
Frequently Asked Questions (PDF, 199 KB)  
IMI Key Messages for Member States (PDF, 154 KB)  
IMI Glossary (PDF, 21 KB)